Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma


Generic Name:
Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma
Project Status:
Project Line:
Reimbursement Review
Project Sub Line:
Therapeutic Review
Project Number:
TR0014-000 - OP0547-000
Effective finish date:

Multiple myeloma (MM) is a hematological cancer that mainly affects individuals older than 65 years of age. Though MM remains incurable, several life-prolonging pharmacotherapies for the treatment of newly diagnosed, relapsed, or refractory MM were reviewed by CADTH and are available or being considered for public reimbursement in Canada. However, at this time, the optimal sequence of therapies is unclear. CADTH completed a Therapeutic Review considering multiple MM drugs and treatment steps in order to help decision-makers develop appropriate pharmaceutical funding policies.

Key Milestones
Draft recommendation(s) posted for stakeholder feedbackJanuary 4, 2024
End of feedback periodJanuary 25, 2024
Updated draft recommendation(s) posted for stakeholder feedbackMarch 7, 2024
End of updated reimbursement recommendation feedback periodMarch 21, 2024
Final recommendation decisionNovember 30, 2023
Date recommendation issuedFebruary 1, 2024
Final summary report postedApril 16, 2024
Final recommendation postedMay 6, 2024
Final updated reimbursement recommendationsMay 6, 2024